---
document_datetime: 2023-09-21 20:21:53
document_pages: 6
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/truberzi-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: truberzi-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.6838876
conversion_datetime: 2025-12-25 01:17:31.992281
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Truberzi

<!-- image -->

<!-- image -->

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                 | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on no longer   | Product Information affected 3   | Summary                                                                                                                                                                                                                               |
|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|-------------------------------------------------------|----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0013            | A.1 - Administrative change - Change in the name and/or address of the MAH                                                                            | 12/02/2020                          |                                                       | SmPC, Labelling and PL           |                                                                                                                                                                                                                                       |
| II/0009/G            | This was an application for a group of variations. Update of sections 4.2, 4.4 and 5.2 of the SmPC in order to update the safety information based on | 19/09/2019                          | 24/10/2019                                            | SmPC and PL authorised           | PK study ELX-PK-01 confirmed the renal excretion route a minor elimination pathway of eluxadoline. In participants with end stage renal disease (ESRD) not yet on dialysis, exposure of eluxadoline was significantly increased (4.2- |

Medicinal product no longer authorised

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

| PSUSA/10528 /201903   | Periodic Safety Update EU Single assessment - eluxadoline                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 03/10/2019         | n/a                  |             | PRAC Recommendation - maintenance   |
|-----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|----------------------|-------------|-------------------------------------|
| PSUSA/10528 /201809   | Periodic Safety Update EU Single assessment - eluxadoline                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 11/04/2019         | n/a                  |             | PRAC Recommendation - maintenance   |
| IB/0010               | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation Medicinal                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 08/03/2019         | n/a                  |             |                                     |
| PSUSA/10528 /201803   | Periodic Safety Update EU Single assessment - eluxadoline                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 04/10/2018         | n/a                  |             | PRAC Recommendation - maintenance   |
| II/0005/G             | This was an application for a group of variations. Update of sections 4.5 and 5.2 of the SmPC in order to update the drug interaction information based on the final report from study 3030-102-002: a single- center, non-randomized, open-label, single-sequence study to evaluate the effect of eluxadoline on the single-dose pharmacokinetics of midazolam in healthy subjects, listed as a category 3 study in the RMP. The package leaflet was updated accordingly. Submission of the final report from study ELX-PH-08: in vitro evaluation of eluxadoline as an inducer of cytochrome P450 (CYP) 1A2 and 3A4 expression in cultured human hepatocytes, listed as a category 3 study in the RMP. Following the assessment of EMEA/H/C/PSUSA/00010528/201703, the RMP was updated to version 2.1 to update the existing important identified risk 'SO spasm' to 'SO spasm | 06/09/2018 product | 09/08/2019 no longer | SmPC and PL | authorised                          |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                     | pancreatitis as a new important identified risk. C.I.11.a - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of wording agreed by the competent authority C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority Medicinal                                                                                  |                                   |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------|
| PSUSA/10528 /201709 | Periodic Safety Update EU Single assessment - eluxadoline 12/04/2018 product                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | PRAC Recommendation - maintenance |
| IA/0006/G           | This was an application for a group of variations. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.4.a - Change to in-process tests or limits applied during the manufacture of the AS - Tightening of in-process limits B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or 06/04/2018 | authorised                        |

<div style=\"page-break-after: always\"></div>

<!-- image -->

<div style=\"page-break-after: always\"></div>

|        | product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes Medicinal   |            |            |                        |
|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|
| T/0001 | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                             | 17/11/2016 | 05/12/2016 | SmPC, Labelling and PL |

<!-- image -->